South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...
Korea Joongang Daily on MSN3d
Celltrion announces 100 billion won share buybackCelltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...
Celltrion, a major Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won ($69 million) worth of its ...
South Koreas K. Pharma and Bio prepare for U.S. 25% pharmaceutical tariff U.S. pharmaceutical tariffs trigger strategic ...
Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...
Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...
This month’s Healio Gastroenterology Exclusive highlights a problem that we as physicians “feel” either directly or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback